한글목차

CD-19 항체 시장 규모는 최근 현저하게 확대하고 있습니다. 2025년 18억 9,000만 달러에서 2026년에는 20억 6,000만 달러로, CAGR 8.7%로 성장할 것으로 예상됩니다. 지난 수년간의 성장에는 단클론항체 기술의 발전, 백혈병 및 림프종 발생률 증가, 면역요법 승인 확대, 종양학 연구의 발전, 혈액학 분야에 대한 자금 지원 증가 등이 주요 요인으로 작용한 것으로 보입니다.

CD19 항체 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 28억 6,000만 달러에 달하고, CAGR은 8.6%가 될 전망입니다. 예측 기간의 성장 요인으로는 세포 및 유전자 치료의 확대, 정밀 종양학의 채용 증가, 병용 면역치료의 확대, 암 발병률의 증가, 전문 종양센터의 발전 등을 들 수 있습니다. 예측 기간의 주요 동향으로는 CD19 표적 면역치료제 사용 증가, B세포 악성종양 치료에서의 채택 확대, CAR-T 세포 치료와의 통합 발전, 단클론항체 개발 확대, 정밀 혈액종양학에 대한 집중 강화 등이 있습니다.

B세포 악성종양 발생률의 증가는 향후 몇 년 동안 CD19 항체 분야의 확장을 주도할 것으로 예상됩니다. B세포 악성 종양은 B세포 림프종, 백혈병 등의 질환을 포함하여 비정상적인 B 림프구에서 유래한 암군으로, 면역 체계에 영향을 미쳐 통제할 수 없는 세포 증식을 유발할 수 있습니다. B세포 악성종양의 증가 추세는 고령화, 유전적 소인, 환경 노출, 생활습관, 진단기술의 향상, 면역기능의 변화 등 여러 요인과 관련이 있습니다. CD19 항체는 악성 B세포 표면의 CD19 단백질을 특이적으로 표적화하여 B세포 악성종양을 치료하고, 정상세포를 보존하면서 악성세포의 제거를 촉진하여 신체의 면역반응을 강화합니다. 예를 들어, 2024년 1월 미국 비영리단체인 미국암협회가 발표한 자료에 따르면, 미국에서는 약 80,620명이 비호지킨림프종 진단을 받을 것으로 예상되며, 약 20,240명(남성 44,590명, 여성 36,030명)이 이 질환으로 인해 사망할 것으로 추산됩니다. 그 결과, B세포 악성종양 발생률의 증가가 CD-19 항체 분야의 성장을 촉진하고 있습니다.

CD-19 항체 분야의 주요 기업들은 특히 혈액악성종양에 대한 암 치료 효과 향상을 목표로 유전자 변형 자가 T세포 면역치료 등 기술 혁신에 집중하고 있습니다. 유전자 변형 자가 T세포 면역치료는 환자 자신의 T세포를 채취하여 암세포를 인식하고 공격하도록 유전자 조작을 한 후 환자의 체내에 재도입하여 질병에 대한 면역반응을 강화하는 치료법입니다. 예를 들어, 2024년 11월 미국 바이오 제약사 오토라스 테라퓨틱스(Autorus Therapeutics)는 재발성 또는 불응성 B세포 전구세포 급성 림프아구성 백혈병(ALL) 성인 환자를 대상으로 한 AUCATZYL(오베카부타겐 오토로이셀)의 미국 FDA 승인을 발표하였습니다. 본 치료제는 과도한 T세포 활성화를 억제하여 독성을 줄이고 치료세포의 지속성을 향상시키도록 설계되어 있습니다. 투약은 1일차와 10일차에 나누어 투여하며, 치료 전 골수 평가에 따라 개별적으로 조정됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

CD19 antibody is a monoclonal antibody that specifically binds to the CD19 protein, a cell surface marker predominantly present on B cells. CD19 plays an essential role in B cell development and is frequently overexpressed in B cell-related cancers, such as some leukemias and lymphomas. These antibodies are utilized in immunotherapy, including CAR-T cell therapy, to treat cancer by guiding the immune system to target CD19-expressing cells.

The primary disease categories in the CD-19 antibody sector include B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and additional conditions. B-cell non-Hodgkin lymphoma is a form of cancer that develops in B lymphocytes, a type of white blood cell crucial for immune system defense. The CD-19 antibody varieties consist of polyclonal and monoclonal antibodies. The methods of administration are intravenous and subcutaneous. The uses of CD-19 antibodies encompass enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry frozen, immunohistochemistry paraffin, and more.

Tariffs have increased the cost of biologic raw materials, cell culture media, and cold chain logistics used in CD19 antibody production. The impact is strongest in monoclonal antibody manufacturing, where process complexity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on global biologics supply chains. Rising tariff related expenses have influenced production economics, capacity planning, and pricing strategies. Tariffs have also encouraged regional biologics manufacturing, expanded local production capacity, and strengthened biopharmaceutical supply chains over the long term.

The cd-19 antibody market research report is one of a series of new reports from The Business Research Company that provides cd-19 antibody market statistics, including cd-19 antibody industry global market size, regional shares, competitors with a cd-19 antibody market share, detailed cd-19 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cd-19 antibody industry. This cd-19 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cd-19 antibody market size has grown strongly in recent years. It will grow from $1.89 billion in 2025 to $2.06 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to advances in monoclonal antibody technology, rising leukemia and lymphoma incidence, expansion of immunotherapy approvals, growth in oncology research, increased funding in hematology.

The cd-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.86 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growth in cell and gene therapies, increasing precision oncology adoption, expansion of combination immunotherapies, rising cancer prevalence, growth in specialty oncology centers. Major trends in the forecast period include rising use of cd19-targeted immunotherapies, increasing adoption in b-cell malignancy treatment, growing integration with car-t cell therapies, expansion of monoclonal antibody development, increased focus on precision hematologic oncology.

The increasing incidence of B-cell malignancies is anticipated to drive the expansion of the CD-19 antibody sector in the coming years. B-cell malignancies are a group of cancers originating from abnormal B lymphocytes, including disorders such as B-cell lymphomas and leukemias, which impact the immune system and can result in uncontrolled cell proliferation. The growing incidence of B-cell malignancies is linked to multiple factors such as an aging population, genetic predispositions, environmental exposures, lifestyle choices, enhanced diagnostic capabilities, and changes in immune function. CD19 antibody treats B-cell malignancies by specifically targeting the CD19 protein on the surface of malignant B cells, promoting their elimination while sparing healthy cells and boosting the body's immune response. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, reported that approximately 80,620 individuals in the USA were projected to be diagnosed with non-Hodgkin lymphoma, and around 20,240 individuals, including 44,590 males and 36,030 females, were estimated to die from the disease. Consequently, the rising incidence of B-cell malignancies is fueling the growth of the CD-19 antibody sector.

Major companies in the CD-19 antibody field are concentrating on technological advancements, such as genetically modified autologous T-cell immunotherapy, to improve the effectiveness of cancer treatments, especially for hematologic malignancies. Genetically modified autologous T-cell immunotherapy involves extracting a patient's own T cells, genetically engineering them to identify and attack cancer cells, and then reintroducing them into the patient's body to strengthen the immune response against the disease. For example, in November 2024, Autolus Therapeutics plc, a US-based biopharmaceutical firm, announced U.S. FDA approval for AUCATZYL (obecabtagene autoleucel), indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This therapy is designed to limit excessive T-cell activation, thereby reducing toxicity and improving the longevity of the therapeutic cells. It is administered as a split-dose infusion on days 1 and 10, with dosing personalized based on a bone marrow evaluation before treatment.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical firm, acquired Gracell Biotechnologies Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to strengthen its cell therapy portfolio by utilizing Gracell Biotechnologies' advanced FasTCAR platform and expertise in developing CD-19 and BCMA-targeted CAR-T therapies. Gracell Biotechnologies Inc. is a China-based clinical-stage biopharmaceutical company focused on discovering and developing innovative cell therapies.

Major companies operating in the cd-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

North America was the largest region in the CD-19 antibody market in 2025. The regions covered in the cd-19 antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cd-19 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD-19 antibody market consists of revenues earned by entities by providing monoclonal antibody therapies, CAR-T cell therapies, diagnostic services, biopharmaceutical research and development, and manufacturing services related to the production of CD-19 targeted treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD-19 antibody market includes the sale of recombinant antibodies, and antibody-based therapies targeting CD19 for research and clinical applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD-19 Antibody Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cd-19 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd-19 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cd-19 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Type: B-Cell Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Acute Lymphoblastic Leukemia; Other Disease Types
• 2) By Type: Polyclonal; Monoclonal
• 3) By Route Of Administration: Intravenous; Subcutaneous
• 4) By Application: Enzyme Linked Immunosorbent Assay; Flow Cytometry; Immunohistochemistry Frozen; Immunohistochemistry Paraffin; Other Applications
• Subsegments:
• 1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Mantle Cell Lymphoma
• 2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL; Treatment-Naive CLL
• 3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL; Philadelphia Chromosome-Positive ALL
• 4) By Other Disease Types: Hairy Cell Leukemia; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Novartis AG; Thermo Fisher Scientific Inc.; Amgen Inc.; Bio-Rad Laboratories Inc.; Miltenyi Biotec GmbH; Abcam Plc; Kite Pharma Inc.; BioLegend Inc.; Xencor Inc.; Juno Therapeutics Inc.; BD Biosciences; Zenas BioPharma Inc.; Cell Signaling Technology Inc.; Santa Cruz Biotechnology Inc.; Novus Biologicals LLC; Tonbo Biosciences Inc.; Bio X Cell Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. CD-19 Antibody Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global CD-19 Antibody Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. CD-19 Antibody Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global CD-19 Antibody Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Use Of Cd19-Targeted Immunotherapies
  • 4.2.2 Increasing Adoption In B-Cell Malignancy Treatment
  • 4.2.3 Growing Integration With Car-T Cell Therapies
  • 4.2.4 Expansion Of Monoclonal Antibody Development
  • 4.2.5 Increased Focus On Precision Hematologic Oncology

5. CD-19 Antibody Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Hematology Centers
• 5.4 Research Institutes
• 5.5 Specialty Cancer Centers

6. CD-19 Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global CD-19 Antibody Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global CD-19 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global CD-19 Antibody Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global CD-19 Antibody Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global CD-19 Antibody Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global CD-19 Antibody Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. CD-19 Antibody Market Segmentation

• 9.1. Global CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
• 9.2. Global CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polyclonal, Monoclonal
• 9.3. Global CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Subcutaneous
• 9.4. Global CD-19 Antibody Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
• 9.5. Global CD-19 Antibody Market, Sub-Segmentation Of B-Cell Non-Hodgkin Lymphoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma
• 9.6. Global CD-19 Antibody Market, Sub-Segmentation Of Chronic Lymphocytic Leukemia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Relapsed Or Refractory CLL, Treatment-Naive CLL
• 9.7. Global CD-19 Antibody Market, Sub-Segmentation Of Acute Lymphoblastic Leukemia, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL
• 9.8. Global CD-19 Antibody Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hairy Cell Leukemia, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma

10. CD-19 Antibody Market Regional And Country Analysis

• 10.1. Global CD-19 Antibody Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global CD-19 Antibody Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific CD-19 Antibody Market

• 11.1. Asia-Pacific CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China CD-19 Antibody Market

• 12.1. China CD-19 Antibody Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India CD-19 Antibody Market

• 13.1. India CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan CD-19 Antibody Market

• 14.1. Japan CD-19 Antibody Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia CD-19 Antibody Market

• 15.1. Australia CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia CD-19 Antibody Market

• 16.1. Indonesia CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea CD-19 Antibody Market

• 17.1. South Korea CD-19 Antibody Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan CD-19 Antibody Market

• 18.1. Taiwan CD-19 Antibody Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia CD-19 Antibody Market

• 19.1. South East Asia CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe CD-19 Antibody Market

• 20.1. Western Europe CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK CD-19 Antibody Market

• 21.1. UK CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany CD-19 Antibody Market

• 22.1. Germany CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France CD-19 Antibody Market

• 23.1. France CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy CD-19 Antibody Market

• 24.1. Italy CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain CD-19 Antibody Market

• 25.1. Spain CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe CD-19 Antibody Market

• 26.1. Eastern Europe CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia CD-19 Antibody Market

• 27.1. Russia CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America CD-19 Antibody Market

• 28.1. North America CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA CD-19 Antibody Market

• 29.1. USA CD-19 Antibody Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada CD-19 Antibody Market

• 30.1. Canada CD-19 Antibody Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America CD-19 Antibody Market

• 31.1. South America CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil CD-19 Antibody Market

• 32.1. Brazil CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East CD-19 Antibody Market

• 33.1. Middle East CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa CD-19 Antibody Market

• 34.1. Africa CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa CD-19 Antibody Market, Segmentation By Disease Type, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. CD-19 Antibody Market Regulatory and Investment Landscape

36. CD-19 Antibody Market Competitive Landscape And Company Profiles

• 36.1. CD-19 Antibody Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. CD-19 Antibody Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. CD-19 Antibody Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

37. CD-19 Antibody Market Other Major And Innovative Companies

• Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

38. Global CD-19 Antibody Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The CD-19 Antibody Market

40. CD-19 Antibody Market High Potential Countries, Segments and Strategies

• 40.1 CD-19 Antibody Market In 2030 - Countries Offering Most New Opportunities
• 40.2 CD-19 Antibody Market In 2030 - Segments Offering Most New Opportunities
• 40.3 CD-19 Antibody Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer